FICAN science webinaari ”What I learned in 20 years studying statins in cancer”

Aika: Ke 10.6. klo 15-16 

Aihe: What I learned in 20 years studying statins in cancer

Puhuja: prof. Teemu Murtola, Tampereen yliopisto ja TAYS

Tällä kertaa webinaarin järjestää FICAN Mid. Webinaariin voit liittyä suoraan tästä linkistä: Liity kokoukseen nyt

Abstract:

Does cholesterol-lowering with statins affect the risk of prostate cancer or the risk of dying of the disease? If so, what would be the mechanism? Are the possible cancer-related effects limited to prostate cancer only, or are they relevant to also other cancer types? In his talk professor Teemu Murtola will discuss the above questions and more based on his research using population-level epidemiological data, in vitro laboratory studies and ultimately randomised clinical trials.

More information about the speaker:

Professor Teemu Murtola works as the professor of Urology at Tampere University, Faculty of Medicine and Health Technology and Chief Physician at Tampere University Hospital, Department of Urology in Pirha. He leads the new Research Center, the Center for Cancer Eradication Research at Tampere University. His research group, Lipid metabolism as targetable weakness of prostate cancer, is a clinical research team with strong commitment to improve prostate cancer care through deeper understanding of biology underlying disease progression and treatment resistance. Their main focus is exploring the roles of lipid and cholesterol metabolism at different phases of prostate cancer progression. They use cell culture models to evaluate prostate cancer cell metabolism at various stages of disease development and treatment resistance. They also perform epidemiological studies using population-based datasets to evaluate how usage of drugs that appeared promising in cell culture models associate with prostate cancer risk and prognosis at population level.  They also carry out investigator -initiated randomised clinical trials.

More information:  https://research.tuni.fi/esto/

Relevat references for this talk:

• Vettenranta et al.: Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. JAMA Oncol. 2022;8;(1):61-68.  DOI: 10.1001/jamaoncol.2021.5672
• Siltari et al: Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. BMJ Journals vol. 12;(4), 2021. https://bmjopen.bmj.com/content/12/4/e050264 or  doi: 10.1136/bmjopen-2021-050264.
• Peltomaa et al.: Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level.  Cancers (Basel). 2022 Jun 14;14(12):2920.   DOI: 10.3390/cancers14122920
• Raittinen et al. : Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial. EBioMedicine. 2021 Jun:68:103432. DOI: 10.1016/j.ebiom.2021.103432
• Murtola et al.: Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy -A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol. 2018 Dec;74(6):697-701. DOI: 10.1016/j.eururo.2018.06.037
• Syvälä et al.: Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells. BBRC. 2016 Dec 2;481(1-2):46-50.  DOI: 10.1016/j.bbrc.2016.11.021